{
    "clinical_study": {
        "@rank": "130948", 
        "arm_group": [
            {
                "arm_group_label": "BI 113608 high dose bid", 
                "arm_group_type": "Experimental", 
                "description": "powder in the bottle for oral solution, oral administration with 240 ml water"
            }, 
            {
                "arm_group_label": "BI 113608 low dose bid", 
                "arm_group_type": "Experimental", 
                "description": "powder in the bottle for oral solution, oral administration with 240 ml water"
            }, 
            {
                "arm_group_label": "BI 113608 medium dose bid", 
                "arm_group_type": "Experimental", 
                "description": "powder in the bottle for oral solution, oral administration with 240 ml water"
            }, 
            {
                "arm_group_label": "BI 113608 high dose qd", 
                "arm_group_type": "Experimental", 
                "description": "powder in the bottle for oral solution, oral administration with 240 ml water"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of the current trial is to evaluate safety, tolerability and pharmacokinetics\n      of multiple rising doses of BI 113608 in healthy male volunteers"
        }, 
        "brief_title": "Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 113608 in Healthy Male Volunteers", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        1. healthy male subjects\n\n        Exclusion criteria:\n\n        1. Any relevant deviation from healthy conditions"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01681277", 
            "org_study_id": "1314.2", 
            "secondary_id": "2012-002536-82"
        }, 
        "intervention": [
            {
                "arm_group_label": "BI 113608 medium dose bid", 
                "description": "powder for oral solution", 
                "intervention_name": "BI 113608 PIB bid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 113608 low dose bid", 
                "description": "powder for oral solution", 
                "intervention_name": "Placebo to BI 113608 PIB bid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 113608 medium dose bid", 
                "description": "powder for oral solution", 
                "intervention_name": "Placebo to BI 113608 PIB bid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 113608 high dose qd", 
                "description": "powder for oral solution", 
                "intervention_name": "Placebo to BI 113608 PIB qd", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 113608 high dose bid", 
                "description": "powder for oral solution", 
                "intervention_name": "Placebo to BI 113608 PIB bid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 113608 high dose bid", 
                "description": "powder for oral solution", 
                "intervention_name": "BI 113608 PIB bid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 113608 low dose bid", 
                "description": "powder for oral solution", 
                "intervention_name": "BI 113608 PIB bid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 113608 high dose qd", 
                "description": "powder for oral solution", 
                "intervention_name": "BI 113608 PIB qd", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "July 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Mannheim", 
                    "country": "Germany"
                }, 
                "name": "1314.2.1 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "4", 
        "official_title": "Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 113608 Powder for Oral Solution in Healthy Male Volunteers q.d. or b.i.d. for 14 Days (a Randomised, Double-blind, Placebo-controlled Within Dose Groups Phase I Trial)", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of participants with adverse events", 
                "safety_issue": "No", 
                "time_frame": "up to 16 weeks"
            }, 
            {
                "measure": "Number of participants with changes from baseline in physical examination including orthostasis test", 
                "safety_issue": "No", 
                "time_frame": "up to 16 weeks"
            }, 
            {
                "measure": "Number of participants with changes from baseline in electrocardiogram (ECG) results", 
                "safety_issue": "No", 
                "time_frame": "up to 16 weeks"
            }, 
            {
                "measure": "Number of participants with significant changes from baseline laboratory measurements", 
                "safety_issue": "No", 
                "time_frame": "up to 16 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01681277"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cmax,ss (maximum measured concentration of the analyte in plasma at steady state)", 
                "safety_issue": "No", 
                "time_frame": "up to 16 weeks"
            }, 
            {
                "measure": "tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state)", 
                "safety_issue": "No", 
                "time_frame": "up to 16 weeks"
            }, 
            {
                "measure": "AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t)", 
                "safety_issue": "No", 
                "time_frame": "up to 16 weeks"
            }, 
            {
                "measure": "t1/2,ss (terminal half-life of the analyte in plasma at steady state)", 
                "safety_issue": "No", 
                "time_frame": "up to 16 weeks"
            }, 
            {
                "measure": "RA,Cmax (Accumulation ratio of the analyte in plasma at steady state after multiple oral administration over a uniform dosing interval t, expressed as ratio of Cmax at steady state and after single dose)", 
                "safety_issue": "No", 
                "time_frame": "up to 16 weeks"
            }, 
            {
                "measure": "RA,AUC (Accumulation ratio of the analyte in plasma at steady state after multiple dose administration over a uniform dosing interval t, expressed as ratio of AUC at steady state and after single dose)", 
                "safety_issue": "No", 
                "time_frame": "up to 16 weeks"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}